Tsuruo T, Iida H, Makishima F, Yamori T, Kawabata H, Tsukagoshi S, Sakurai Y
Cancer Chemother Pharmacol. 1985;14(1):30-3. doi: 10.1007/BF00552721.
Verapamil, a calcium antagonist, inhibited both experimental (IV inoculation of tumor cells) and spontaneous metastasis (SC inoculation) of the highly metastatic B16 melanoma and colon adenocarcinoma 26 cell lines. Verapamil treatment resulted in a maximum 80% inhibition of metastases, the degree of inhibition varying among the different metastatic systems. Verapamil inhibited platelet aggregation induced by these tumor cell lines, the patterns of inhibition being different for B16 melanoma and colon adenocarcinoma. The inhibition of platelet aggregation induced by tumor cells is proposed as a mechanism by which the calcium antagonist exerts its antimetastatic effect. These results, together with our previous findings that calcium antagonists can increase the cytotoxicity of drugs in tumor cells with induced or inherent drug resistance by inhibiting outward transport of the drug, indicate that calcium antagonists have potential as a new class of adjuvant agents in the field of cancer chemotherapy.
维拉帕米,一种钙拮抗剂,抑制了高转移性B16黑色素瘤和结肠腺癌26细胞系的实验性转移(静脉接种肿瘤细胞)和自发性转移(皮下接种)。维拉帕米治疗导致转移的最大抑制率达80%,不同转移系统中的抑制程度有所不同。维拉帕米抑制了这些肿瘤细胞系诱导的血小板聚集,B16黑色素瘤和结肠腺癌的抑制模式有所不同。肿瘤细胞诱导的血小板聚集抑制被认为是钙拮抗剂发挥其抗转移作用的一种机制。这些结果,连同我们之前的发现,即钙拮抗剂通过抑制药物的外向转运可增加诱导性或固有耐药性肿瘤细胞中药物的细胞毒性,表明钙拮抗剂在癌症化疗领域有作为新型辅助药物的潜力。